Related Experiment Videos
Rituximab therapy of B-cell neoplasms
1St. Luke's-Roosevelt Hospital Center, New York, NY 10019, USA.
Clinical Lymphoma
|November 15, 2001
Summary
Rituximab, an anti-CD20 antibody, is a breakthrough therapy for B-cell cancers. Ongoing trials explore its efficacy in various hematological malignancies, often combined with chemotherapy for high response rates.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Rituximab, an anti-CD20 monoclonal antibody, has transformed hematological malignancy treatment.
- Initially approved for relapsed/refractory follicular non-Hodgkin's lymphoma (NHL), its use has expanded to other CD20+ B-cell neoplasms.
Purpose of the Study:
- To review the current clinical trials involving rituximab.
- To discuss the significance of rituximab in treating B-cell malignancies.
Main Methods:
- Review of recent studies and ongoing phase II and III clinical trials of rituximab.
- Analysis of rituximab's efficacy as a single agent and in combination with chemotherapy.
Main Results:
- Rituximab demonstrates activity in various CD20-expressing hematological malignancies.
- Combination therapy with chemotherapy yields response rates of 90%-95% in NHL patients.
Conclusions:
- Rituximab is a significant therapeutic advancement for B-cell neoplasms.
- Further clinical research is crucial to define rituximab's role and impact on patient survival.